NEWS ANALYSIS | Sept 20, 2026 | Kratom Truth Project
NIH Filed to Develop a Prescription 7-OH Replacement. 30 Days Later, DEA Moved to Schedule the Natural Version.
On June 1, 2026, the National Institutes of Health announced that its Investigational New Drug application for purified mitragynine had taken effect with the FDA. The compound, designated MG001, is being developed as a prescription treatment for opioid use disorder in a collaboration between NIH, the University of Florida, and the National Institute on Drug Abuse. The IND authorization cleared the path for the first randomized, double-blind, placebo-controlled Phase 1 human clinical trial of mitragynine, expected to begin September 2026.
Thirty days later, on July 1, 2026, the Drug Enforcement Administration filed an emergency notice of intent to schedule 7-hydroxymitragynine and three synthetic derivatives as Schedule I controlled substances.
Both agencies report to the Department of Health and Human Services. The same department was simultaneously developing a prescription replacement for kratom's active compounds through one arm while moving to schedule the natural version through another.
This is not a coincidence. It is a sequence.
What an IND Actually Means
An Investigational New Drug application is not a preliminary research proposal. It is a formal authorization from the FDA allowing a specific compound to enter human clinical trials. Receiving an IND represents a substantial investment of time, resources, and regulatory work. It is the committed beginning of a commercial pharmaceutical development pathway.
MG001 is purified mitragynine. Not a modified analog. Not a deuterated derivative. The same alkaloid that comprises 60-70% of every kratom leaf, isolated and prepared as a pharmaceutical compound. The prescription version of what millions of Americans are currently buying for $30-60 a month without a prescription.
NIDA director Nora Volkow stated on June 1: "This IND is a major step toward expanding treatment options for the millions of Americans struggling with opioid use disorder." A federal agency director characterizing a kratom-derived pharmaceutical as a major step forward while her department's other arm was preparing to schedule the natural version is the entire story in one sentence.
The HHS Connection
NIH is part of the Department of Health and Human Services. The FDA, which received and approved the MG001 IND, is also part of HHS. The scheduling recommendation that led to the DEA's July 1 notice originated from HHS through its FDA arm. Secretary Kennedy oversees both.
This is not two agencies with competing priorities accidentally arriving at contradictory outcomes. This is one department, through its various arms, simultaneously advancing a prescription replacement for kratom's active compounds while creating the regulatory environment that makes that prescription replacement commercially necessary.
The natural version, available without a prescription for $30-60 a month, is being removed from the market by one arm of HHS. The prescription version, which will require a doctor's visit, an insurance authorization, and a pharmacy copay, is being developed by another arm of the same department.
The HEAL Initiative
The MG001 trial is funded through the NIH HEAL Initiative, Helping to End Addiction Long-term, established in 2018 as a federal response to the opioid crisis. Federal opioid crisis money is being used to develop a prescription pharmaceutical from kratom's primary alkaloid. The same public health emergency that has driven demand for affordable harm reduction options like kratom is now funding the development of a prescription replacement for it.
The OUD-Only Pathway
If MG001 achieves FDA approval through this process, it will only be approved for opioid use disorder treatment, not as a pain reliever. A separate IND application would be required for that indication. This matters because OUD treatment represents only one of the major conditions people currently manage with kratom. Chronic pain, anxiety, sleep disruption, and general harm reduction from other substances are all outside the current MG001 approval pathway. Each would require its own pharmaceutical development program. The commercial pipeline for kratom-derived prescription drugs is potentially far larger and longer-running than a single OUD indication suggests.
The Commercial Math
People currently managing opioid use disorder with kratom pay $30-60 per month without a prescription. People managing the same condition through the clinical system with Suboxone or methadone pay $300-500 per month. SAMHSA data shows only 1 in 5 people with OUD receives any medication-assisted treatment. For the 80% who do not, affordable accessible options like kratom fill a gap the clinical system cannot reach.
When MG001 receives FDA approval and the natural version is no longer legally available, the market does not disappear. It migrates. From an unpatentable botanical at $30-60 a month to a prescription pharmaceutical at clinical pricing. The revenue opportunity being created by the scheduling action is the same revenue opportunity the IND is designed to capture.
The Precedent
This pattern has a documented precedent. CBD was classified as a controlled substance as part of cannabis. GW Pharmaceuticals spent years developing Epidiolex, a purified CBD pharmaceutical. The FDA approved it in 2018 for epilepsy at over $30,000 per year. The same compound that was part of a Schedule I substance became a prescription drug at a massive markup. Same molecule, same effects. The difference was a patent and a pharmaceutical company behind it. Kratom is earlier in the same arc.
A Note on the DEA's Framing
The DEA has stated that the scheduling targets synthetic and concentrated 7-OH above a specified threshold, and has indicated it is not intended to affect botanical kratom leaf or the MG001 trial due to lower peak 7-OH exposures. This framing deserves scrutiny. The proposed threshold of 0.05% 7-OH by weight would sweep in naturally occurring botanical kratom leaf, where 7-OH occurs at concentrations up to 0.21% in the FDA's own consumer sample dataset of 341 products. A threshold designed ostensibly to target concentrated synthetic products would by its own terms eliminate access to the natural plant. The comment period on this action received substantial scientific pushback and was extended before closing on September 10, 2026.
The Primary Sources
Every claim in this article is drawn from public documents. The NIH IND announcement is from the NIH press release dated June 1, 2026. The DEA scheduling notice is FR Doc. 2026-13580, available in the Federal Register. The HHS organizational structure is public record. The NIDA director quote is from the June 1 NIH press release. The SAMHSA treatment gap data is from the National Survey on Drug Use and Health. The FDA consumer sample dataset is from Sharma et al. 2025.
The 30-day window between these two federal actions is not an interpretation or an inference. It is a documented sequence of events in the public record.
Readers are encouraged to consult the primary documents directly.
The Kratom Truth Project documents the financial conflicts and scientific record behind kratom policy. The full investigation into the patent trail and regulatory history is at kratomtruthproject.org/how-a-crisis-gets-built. The pharmaceutical patent documentation is at kratomtruthproject.org/the-patent-race-synthetic-kratom-the-cannabis-playbook.
